A Phase 1 Study of KH902, a Vascular Endothelial Growth Factor Receptor Decoy, for Exudative Age-Related Macular Degeneration

Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases

“…10,11 Previous studies indicated that FP3 had promise as a local antiangiogenic treatment of human CNV (choroidal neovascularization)-related AMD (age-related macular degeneration). 10,[12][13][14] In subsequent studies, it was demonstrated that FP3 has an inhibitory efficacy in VEGF-mediated proliferation and migration of human umbilical vein endothelial cells, and in VEGF-mediated vessel sprouting of rat aortic ring in vitro. 11 It was also demonstrated that FP3 has an antitumor effect in non-small cell lung cancer (A549), breast cancer (MCF-7), hepatocellular carcinoma (HepG2) and colorectal cancer (LoVo) cell lines xenograft models, 11,15 and patient-derived tumor tissue (PDTT) xenograft models of gastric carcinoma 16 and colon carcinoma with lymphatic and hepatic metastases 17 in nude mice.…”

Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease

“…PTX-2 has been reported to reduce M1 macrophage activation and stimulate antiinflammatory M2 type (Mreg) macrophages (2,5,24,25). We therefore evaluated macrophage populations in glomeruli and the interstitium.…”

Clinical Characteristics and Current Treatment of Age-Related Macular Degeneration

“…Strategies under investigation include inhibition of platelet-derived growth factor (Boyer 2013), and other mechanisms of VEGF blockade including anti-VEGF gene therapy. (Lukason et al 2011;Zhang et al 2011b;Campochiaro et al 2013).…”